Skip to main content
TipRanks
Go Ultimate75% OFF

SELLAS Life Sciences Group (RXK3) AI Stock Analysis

2 Followers
DE:RXK3

SELLAS Life Sciences Group

(XETRA:RXK3)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Positive Phase 3 efficacyThe positive Phase 3 REGAL result materially strengthens GPS as a potential oncology product and provides clinical validation for SELLAS’s lead program. If confirmed through regulatory review, the survival benefit could support future approval, adoption, and a durable commercial revenue opportunity.
Negative Factors
Pre-revenue business modelSELLAS has no established product revenue base to absorb operating costs because its lead candidates remain in development. Persistent losses therefore depend on continued external financing or future clinical success, making financial performance highly sensitive to regulatory and development outcomes.

SELLAS Life Sciences Group (RXK3) vs. iShares MSCI Germany ETF (EWG)

-250%0%250%500%750%1000%1250%1500%DE:RXK3+856.55%EWG+1.23%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 2.78B
Dividend Yield
―
Average Volume (3M)
1,444
Price to Earnings (P/E)
-68.7
Beta (1Y)
-0.46
Revenue Growth
―
EPS Growth
34.25%
Country
Germany
Employees
13
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

SELLAS Life Sciences Group Business Overview & Revenue Model

Company Description

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a p...

SELLAS Life Sciences Group Risk Analysis

SELLAS Life Sciences Group disclosed 77 risk factors in its most recent earnings report. SELLAS Life Sciences Group reported the most risks in the "Tech & Innovation" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

0 New Risks

SELLAS Life Sciences Group Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

DE:RXK3 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
XNCRXNCR61Neutral$2.55B-21.18-21.29%―33.55%11.51%
ARVNARVN60Neutral$441.37M-43.07-2.00%―-11.85%81.44%
IOVAIOVA56Neutral$3.38B-13.02-29.71%―51.31%56.78%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
ORICORIC48Neutral$800.27M-5.04-40.99%――15.37%
NBTXNBTX41Neutral$1.45B-22.1389.71%―――

* Healthcare Sector Average

Performance Comparison

0%500%1000%DE:RXK3XNCRIOVAARVNORICNBTXDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
DE:RXK3 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:RXK3Sellas Life Sciences Group12.5511.20832.39%
XNCRXencor Inc.33.2616.5298.69%
IOVAIovance Biotherapeutics6.904.40176.00%
ARVNArvinas Holding Company6.46-5.31-45.11%
ORICOric Pharmaceuticals Inc7.36-4.43-37.57%
NBTXNanobiotix Sa ADR26.504.5020.45%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.